The CDMO Capacity Crunch With Discovery Labs' Audrey Greenberg and Iovance Biotherapeutics' Sumit Verma
Business Of Biotech
00:00
CDMO's and the Hybrid Model
Vance: We have been partnering with the various CDMO's over the past couple of years to support their clinical programs and product supply chain network. The key factors that our leadership team concluded in its initial journey in engaging with CDMO partners was around the access to and experience in the technology and science needed for tilt therapy. While we had brilliant individuals in our Tampa facility performing bench top and lab work associated with our proprietary till we weren't sure that we could do this on our own. It would make sense for us to utilize that talent from the CDMOs as well.
Transcript
Play full episode
